Science

Jul 27, 2025, 04:16

Yüksel Ürün: A Promising Option for Non–Clear-Cell Renal Cell Carcinoma

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X about recent paper by Martin H. Voss et al., published in European Urology.

“Updated results from KEYNOTE-B61:

First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows:

ORR 51%
CR in 8.2%
Median DOR 19.5 mo

A promising option for nccRCC.”

Title: First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial

Authors: Martin H. Voss, Howard Gurney, Vagif Atduev, Cristina Suarez, Miguel A. Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Jae Lyun Lee, Taron Nalbandian, Viktor Stus, Thomas Ferguson, Pawel Wiechno, Erhan Gokmen, Louis Lacombe, Craig Gedye, Jerry Cornell, Manish Sharma, Joseph E. Burgents, Laurence Albiges

Read The Full Article at European Urology.

Yüksel Ürün: A Promising Option for Non–Clear-Cell Renal Cell Carcinoma

More posts featuring Yüksel Ürün on OncoDaily.

cancer Craig Gedye Cristina Suárez David Pook Erhan Gokmen european urology Howard Gurney Jae Lyun Lee Jerry Cornell Joseph E. Burgents Laurence Albiges Louis Lacombe Manish Sharma Martin H. Voss Miguel A. Climent Non-clear cell renal cell carcinoma OncoDaily Oncology Pawel Wiechno Philippe Barthélémy Piotr Tomczak Taron Nalbandian Thomas Ferguson Vagif Atduev Viktor Stus Yüksel Ürün

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC